BIO-TECHNE Corp
Form 8-K
May 03, 2016

UNITED STATES	
SECURITIES AND	EXCHANGE COMMISSION

Washington, DC 20549

# FORM 8-K

# **Current Report**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2016

#### **BIO-TECHNE CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

Minnesota 0-17272 41-1427402

 $\begin{array}{ll} \text{(State or Other Jurisdiction of} \\ \text{(Commission File Number)} \\ \text{(I.R.S. Employer Identification} \\ \text{Number)} \end{array}$ 

# **614 McKinley Place NE**

# Minneapolis, MN 55413

(Address of Principal Executive Offices) (Zip Code)

# Edgar Filing: BIO-TECHNE Corp - Form 8-K

(612) 379-8854 (Registrant's Telephone Number, Including Area Code)
Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### **Item 2.02 Results of Operations and Financial Condition**

A copy of the press release issued by Bio-techne Corporation on May 3, 2016, describing the results of operations for the quarter ended March 31, 2016 and its financial condition as of March 31, 2016, is attached hereto as Exhibit 99.1.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### **Item 8.01 Other Events**

A copy of the press release issued by Bio-techne Corporation on May 3, 2016, announcing a cash dividend is attached hereto as Exhibit 99.2.

#### **Item 9.01 Financial Statements and Exhibits**

- (d) Exhibits
- 99.1 Press Release, dated May 3, 2016, announcing results of operations.
- 99.2 Press Release, dated May 3, 2016, announcing a cash dividend.

# Edgar Filing: BIO-TECHNE Corp - Form 8-K

SIGN.	ΔΤΙ	IRF
DIUIN.	$\Delta I $	JICL

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TECHNE CORPORATION

Date: May 3, 2016 By: /s/ Charles R. Kummeth

Charles R. Kummeth

President and Chief Executive Officer

# **EXHIBIT INDEX**

# Exhibit No. Description

- 99.1 Press Release, dated May 3, 2016, announcing results of operations
- Press Release, dated May 3, 2016, announcing cash dividend.